RxDoctor Payments Data

Roy Kellerman, MD

Internal Medicine · Bloomfield, CTNPI 1083780605

Payments from drug & device makers

$14,595in general payments, 2019–2025

Across 724 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • Bayer$711
  • Abbott$699
  • plus $7K from 37 others

What the payments were for

  • Consulting fees$1,0007%
  • Travel & lodging$270%
  • Food & beverage$13,51493%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,595 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$34,051
Medicare patients
102
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide208$354,643
FarxigaDapagliflozin Propanediol152$154,632
JardianceEmpagliflozin151$154,000
EliquisApixaban120$119,823
Avonex Pen (4 Pack)Interferon Beta-1a13$105,733
OzempicSemaglutide74$95,422
TrulicityDulaglutide35$62,332
TradjentaLinagliptin52$49,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$45,837
JanuviaSitagliptin Phosphate34$37,756
MounjaroTirzepatide27$35,957
JanumetSitagliptin Phos/Metformin Hcl24$35,278
Soliqua 100-33Insulin Glargine/Lixisenatide28$26,944
LinzessLinaclotide31$24,511
JentaduetoLinagliptin/Metformin Hcl20$23,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,559$450,065282 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$570$226,668223 claims
AstraZenecaFarxiga$1,754$154,632152 claims
PfizerEliquis$1,010$119,823120 claims
Lilly USA, LLCTrulicity, Mounjaro$1,830$98,28962 claims
MerckJanuvia, Janumet$264$73,03558 claims
GSKTrelegy Ellipta$286$45,83769 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$513$26,94428 claims
AbbVieLinzess$512$24,51131 claims
NovartisEntresto$478$18,11919 claims
Johnson & JohnsonXarelto$380$16,93812 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$316$15,88123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →